Developing as a promising advance in the battle against obesity, Retatrutide is capturing considerable attention . This treatment combines the action of two known GLP-1 receptor agonists, liraglutide, with an additional glucose-dependent incretin component. Initial clinical results have indicated impressive fat loss in people with excessive weight